Citation Impact
Citing Papers
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
2010 Standout
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
2012 Standout
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Thiazolidinediones
2004 Standout
The safety of statins in clinical practice
2007
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
2002
Caenorhabditis elegans pathways that surveil and defend mitochondria
2014 StandoutNatureNobel
Pioglitazone
2006
The metabolic syndrome
2010 Standout
Metabolism and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Humans
2009
Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure–Activity Relationships and Discovery Strategies To Mitigate Drug–Drug Interaction Risks
2012
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
2014 Standout
Rosuvastatin for the Treatment of Hypercholesterolemia
2005
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
The metabolic syndrome
2005 Standout
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
2010 Standout
Safety Considerations with Fibrate Therapy
2006
Statin Safety: A Systematic Review
2006
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Excretion and ecotoxicity of pharmaceutical and personal care products in the environment
2005
Pitavastatin: Efficacy and Safety Profiles of A Novel Synthetic HMG‐CoA Reductase Inhibitor
2003
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
2010
Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil
2004
Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans
2004
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2012 Standout
Statin-Associated Myopathy
2003
Progress and challenges in translating the biology of atherosclerosis
2011 StandoutNature
Type 2 diabetes mellitus
2015 Standout
Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering Drugs
2004
A review on the occurrence of micropollutants in the aquatic environment and their fate and removal during wastewater treatment
2014 Standout
Drug Treatment of Hyperlipidaemia
2010
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
2004
Comparative pharmacology of rosuvastatin
2003
Glycaemic control in type 2 diabetes: Targets and new therapies
2009
Metabolic and Additional Vascular Effects of Thiazolidinediones
2002
Traditional usages, botany, phytochemistry, pharmacology and toxicology of Polygonum multiflorum Thunb.: A review
2014 Standout
Combination therapy in dyslipidemia: Where are we now?
2014
Diagnosis and Management of the Metabolic Syndrome
2005 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
2008 Standout
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals
2014 Standout
Update on the Discovery and Development of Cholesteryl Ester Transfer Protein Inhibitors for Reducing Residual Cardiovascular Risk
2013
Dissemination and publication of research findings: an updated review of related biases
2010 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
A Prospective, Randomized Comparison of the Metabolic Effects of Pioglitazone or Rosiglitazone in Patients With Type 2 Diabetes Who Were Previously Treated With Troglitazone
2002
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Green synthesis of zinc oxide nanoparticles using Hibiscus subdariffa leaf extract: effect of temperature on synthesis, anti-bacterial activity and anti-diabetic activity
2014 Standout
Beneficial Vascular and Metabolic Effects of Peroxisome Proliferator-Activated Receptor-α Activators
2005
Pharmaceuticals of Emerging Concern in Aquatic Systems: Chemistry, Occurrence, Effects, and Removal Methods
2019 Standout
Therapeutic Roles of Peroxisome Proliferator–Activated Receptor Agonists
2005
Rosuvastatin safety: lessons from the FDA review and post-approval surveillance
2004
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
2011 StandoutNobel
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
2012 Standout
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
2004 Standout
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health.
1998 Standout
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
2005 Standout
Prescribed drugs containing nitrogen heterocycles: an overview
2020 Standout
Works of Brad Roadcap being referenced
Interactions between Simvastatin and Troglitazone or Pioglitazone in Healthy Subjects
2001
Effect of Sitagliptin on the Pharmacokinetics of Simvastatin
2009
Quantitation of simvastatin and its ?-hydroxy acid in human plasma by liquid-liquid cartridge extraction and liquid chromatography/tandem mass spectrometry
2000
Assessment of the CYP3A‐Mediated Drug Interaction Potential of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Volunteers
2008
Mechanistic Studies on Metabolic Interactions between Gemfibrozil and Statins
2002